Reverberations for Ebos in Chemist Warehouse reverse listing

Reverberations for Ebos in Chemist Warehouse reverse listing
Sigma shareholders might well ask themselves if they're paying too much. (Image: NZME)
Paul McBeth
Discount pharmacist Chemist Warehouse’s reverse takeover of drugmaker Sigma Healthcare to build Australia’s biggest pharmacy group won’t immediately dent Ebos Group and may even offer some opportunities down the road. The discount pharmacist found its route onto the Australian securities exchange (ASX) via a reverse listing of Sigma, where Sigma will borrow A$1 billion (NZ$1.07b) from ANZ and National Australia Bank, give A$700m of that to the Chemist Warehouse shareholders and issue them shares equivalent to 85.8% of the...

More Markets

Iran conflict underscores dairy’s early-season risk warnings
Primary Sector

Iran conflict underscores dairy’s early-season risk warnings

The Israel-Iran war raises logistics risks for dairy but prices likely to remain steady.

Fletcher Building’s FY result won’t be pretty
Markets

Fletcher Building’s FY result won’t be pretty

No dividends will be paid until the debt target is met. 

Fletcher’s down 3.6%; NZX misses ceasefire rally
Markets Market Close

Fletcher’s down 3.6%; NZX misses ceasefire rally

 Channel Infrastructure has benefited from tensions in the Middle East, an analyst said.

Gregor Thompson 24 Jun 2025
Fletcher's restructuring, impairment costs could hit $781m
Infrastructure

Fletcher's restructuring, impairment costs could hit $781m

It expects ebit of $370m to $375m before significant items. 

Rebecca Howard 24 Jun 2025